Application of C1-esterase inhibitor during reperfusion of ischemic myocardium: dose-related beneficial versus...

Area of Science:

• Cardiovascular Research
• Immunology
• Pharmacology

Background:

• Complement activation exacerbates myocardial injury during reperfusion.
• C1-esterase inhibitor (C1-INH) shows cardioprotective effects in experimental models.
• Concerns exist regarding C1-INH safety in newborns, necessitating dosage evaluation.

Purpose of the Study:

• To investigate the dose-dependent effects of C1-INH on myocardial reperfusion injury.
• To determine the optimal dosage of C1-INH for cardioprotection.
• To assess the safety profile of C1-INH at various doses.

Main Methods:

• A pig model of myocardial ischemia-reperfusion (60 min occlusion, 120 min reperfusion).
• Intravenous administration of C1-INH (40, 100, 200 IU/kg) before reperfusion.
• Assessment of myocardial injury, complement activation (C3a, C5a), and cardiac biomarkers (creatine kinase, troponin T).

Main Results:

• C1-INH at 40 IU/kg significantly reduced myocardial necrosis (44.1% vs 76.7%) and suppressed C3a/C5a generation.
• Lowered creatine kinase and troponin T levels were observed with the 40 IU/kg dose.
• No cardioprotection was seen with 100 IU/kg C1-INH; 200 IU/kg induced severe side effects and coagulation disorders.

Conclusions:

• The correct dosage of C1-INH provides significant protection against reperfusion-induced myocardial damage.
• Doses of 100 IU/kg or higher are associated with detrimental side effects, likely due to procoagulatory actions.
• Dosage is critical for the safe and effective use of C1-INH in managing myocardial ischemia-reperfusion injury.